抑制3型脱碘酶表达可通过上调过氧化物酶体增殖物激活受体γ共激活因子1α改善脓毒症骨骼肌线粒体功能
该研究在大鼠胫骨前肌用腺相关病毒靶向抑制Dio3表达并行盲肠结扎穿孔(CLP)建模,分shNC+Sham、shD3+Sham、shNC+CLP、shD3+CLP四组,每组8只;体外用慢病毒干扰C2C12成肌细胞Dio3并予脂多糖处理。结果显示CLP使骨骼肌Dio3蛋白升高(Dio3/β-Tubulin:3.32±0.70 vs. 1.00±0.49,P<0.05),抑制Dio3后T3调控基因THRα、THRβ、MCT10 mRNA恢复,线粒体数目增加、形态改善,PGC1α转录与蛋白表达升高。体外抑制Dio3促进PGC1α向核周及核内转位,降低其乙酰化水平并升高SIRT1;SIRT1抑制剂EX527可逆转PGC1α蛋白升高。作者结论为抑制Dio3通过激活SIRT1降低PGC1α乙酰化、促进其核转位,从而保护脓毒症骨骼肌线粒体。
要点
- CLP脓毒症大鼠骨骼肌Dio3蛋白较shNC+Sham组升高(Dio3/β-Tubulin:3.32±0.70 vs. 1.00±0.49,P<0.05),shD3+CLP组较shNC+CLP组降至1.42±0.54(P<0.05)。
- 抑制Dio3后T3调控基因恢复:THRα mRNA 0.67±0.05 vs. 0.33±0.01、THRβ mRNA 0.94±0.05 vs. 0.67±0.02、MCT10 mRNA 0.65±0.03 vs. 0.57±0.02(均P<0.05,shD3+CLP vs. shNC+CLP)。
- shD3+CLP组骨骼肌线粒体数目较shNC+CLP组增加(11.250±2.063 vs. 10.375±1.375 cells/HP,P<0.05),电镜示线粒体损伤明显改善。
- shD3+CLP组PGC1α mRNA(1.49±0.13 vs. 0.68±0.06)与蛋白(0.76±0.02 vs. 0.62±0.04)均较shNC+CLP组升高(均P<0.05)。
- 体外shD3+LPS组乙酰化PGC1α降低(0.59±0.01 vs. 1.24±0.01)、SIRT1升高(1.04±0.04 vs. 0.58±0.03),EX527使PGC1α蛋白降至0.92±0.03 vs. 1.58±0.03(P<0.05)。
适用人群与场景
- 体内实验:雄性Sprague-Dawley(SD)大鼠,胫骨前肌靶向干预Dio3后行盲肠结扎穿孔(CLP)建立脓毒症模型,随机分为shNC+Sham、shD3+Sham、shNC+CLP、shD3+CLP四组,每组8只。
- 体外实验:C2C12成肌细胞,慢病毒干扰Dio3表达后以脂多糖(LPS)处理24小时构建内毒素细胞模型,分为shNC、shD3、shNC+LPS、shD3+LPS四组。
诊断标准与关键阈值
- 脓毒症模型:大鼠采用盲肠结扎穿孔(CLP)建模。
- 内毒素细胞模型:C2C12细胞以脂多糖(LPS)处理24小时。
处置流程与药物剂量
- 体内实验采用腺相关病毒(AAV)在SD大鼠胫骨前肌特异性靶向Dio3表达,随后行CLP建模,建模后取胫骨样本行Western blotting、RT-qPCR与透射电镜检测。
- 体外实验采用慢病毒干扰C2C12成肌细胞Dio3表达,并以LPS处理24小时;以免疫荧光共定位分析PGC1α胞内分布,以免疫共沉淀联合Western blotting评估PGC1α乙酰化水平。
- 体外以EX527抑制SIRT1活性后检测PGC1α蛋白表达,用于验证SIRT1通路。
研究设计与关键结果
- 体内实验:与shNC+Sham组比较,shNC+CLP组骨骼肌Dio3蛋白表达显著升高(Dio3/β-Tubulin:3.32±0.70 vs. 1.00±0.49,P<0.05),shD3+Sham组无显著差异;shD3+CLP组Dio3表达较shNC+CLP组明显降低(1.42±0.54 vs. 3.32±0.70,P<0.05)。
- 与shNC+CLP组比较,shD3+CLP组T3调控基因表达恢复:THRα mRNA(2-ΔΔCt)0.67±0.05 vs. 0.33±0.01、THRβ mRNA(2-ΔΔCt)0.94±0.05 vs. 0.67±0.02、MCT10 mRNA(2-ΔΔCt)0.65±0.03 vs. 0.57±0.02,均P<0.05。
- 电镜形态分析提示shNC+CLP组骨骼肌线粒体损伤明显,shD3+CLP组明显改善;与shNC+Sham组比较,shNC+CLP组线粒体数目显著减少(cells/HP:10.375±1.375 vs. 13.750±2.063,P<0.05),shD3+CLP组较shNC+CLP组显著增加(11.250±2.063 vs. 10.375±1.375,P<0.05)。
- mtDNA表达:shNC+CLP组较shNC+Sham组明显降低(copies:0.842±0.035 vs. 1.002±0.064,P<0.05);shD3+CLP组与shNC+CLP组间未检测到差异,但较shD3+Sham组显著升高(copies:0.758±0.035 vs. 0.474±0.050,P<0.05)。
- shD3+CLP组PGC1α转录与蛋白水平均较shNC+CLP组显著改善:PGC1α mRNA(2-ΔΔCt)1.49±0.13 vs. 0.68±0.06,PGC1α/β-Tubulin 0.76±0.02 vs. 0.62±0.04,均P<0.05。
- 体外实验:C2C12细胞LPS处理24小时后PGC1α细胞定位变得弥散;干扰Dio3表达促进PGC1α向核周区域及细胞核转位。
- shD3+LPS组乙酰化PGC1α水平显著低于shNC+LPS组(乙酰化PGC1α/β-Tubulin:0.59±0.01 vs. 1.24±0.01,P<0.05);抑制Dio3后去乙酰化酶SIRT1表达显著升高(SIRT1/β-Tubulin:1.04±0.04 vs. 0.58±0.03,P<0.05)。
- 以EX527抑制SIRT1活性后,PGC1α蛋白表达较shD3+LPS组明显降低(PGC1α/β-Tubulin:0.92±0.03 vs. 1.58±0.03,P<0.05)。
证据类型、等级与局限
- 证据类型:动物实验(SD大鼠CLP脓毒症模型)与体外细胞实验(C2C12成肌细胞LPS模型)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,抑制骨骼肌Dio3可通过激活SIRT1降低PGC1α乙酰化、促进PGC1α核转位,从而对脓毒症诱导的骨骼肌线粒体损伤提供保护;该结论来自大鼠与C2C12细胞实验。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the protective effects and mechanisms of targeted inhibition of type 3 deiodinase (Dio3) on skeletal muscle mitochondria in sepsis.
METHODS: (1) In vivo experiments: adeno-associated virus (AAV) was employed to specifically target Dio3 expression in the anterior tibial muscle of rats, and a septic rat model was generated using cecal ligation and puncture (CLP). The male Sprague-Dawley (SD) rats were divided into shNC+Sham group, shD3+Sham group, shNC+CLP group, and shD3+CLP group by random number table method, with 8 rats in each group. After CLP modeling, tibial samples were collected and Western blotting analysis was conducted to assess the protein levels of Dio3, peroxisome proliferator-activated receptor-γ coactivator-1α (PGC1α), and silence-regulatory protein 1 (SIRT1). Real-time fluorescence quantitative polymerase chain reaction (RT-qPCR) was utilized to examine mRNA expression of genes including thyroid hormone receptors (THRα, THRβ), monocarboxylate transporter 10 (MCT10), mitochondrial DNA (mtDNA), and PGC1α. Transmission electron microscopy was employed to investigate mitochondrial morphology. (2) In vitro experiments: involved culturing C2C12 myoblasts, interfering with Dio3 expression using lentivirus, and constructing an endotoxin cell model by treating cells with lipopolysaccharide (LPS). C2C12 cells were divided into shNC group, shD3 group, shNC+LPS group, and shD3+LPS group. Immunofluorescence colocalization analysis was performed to determine the intracellular distribution of PGC1α. Co-immunoprecipitation assay coupled with Western blotting was carried out to evaluate the acetylation level of PGC1α.
RESULTS: (1) In vivo experiments: compared with the shNC+Sham group, the expression of Dio3 protein in skeletal muscle of the shNC+CLP group was significantly increased (Dio3/β-Tubulin: 3.32±0.70 vs. 1.00±0.49, P < 0.05), however, there was no significant difference in the shD3+Sham group. Dio3 expression in the shD3+CLP group was markedly reduced relative to the shNC+CLP group (Dio3/β-Tubulin: 1.42±0.54 vs. 3.32±0.70, P < 0.05). Compared with the shNC+CLP group, the expression of T3-regulated genes in the shD3+CLP group were restored [THRα mRNA (2-ΔΔCt): 0.67±0.05 vs. 0.33±0.01, THRβ mRNA (2-ΔΔCt): 0.94±0.05 vs. 0.67±0.02, MCT10 mRNA (2-ΔΔCt): 0.65±0.03 vs. 0.57±0.02, all P < 0.05]. Morphology analysis by electron microscopy suggested prominent mitochondrial damage in the skeletal muscle of the shNC+CLP group, while the shD3+CLP group exhibited a marked improvement. Compared with the shNC+Sham group, the shNC+CLP group significantly reduced the number of mitochondria (cells/HP: 10.375±1.375 vs. 13.750±2.063, P < 0.05), while the shD3+CLP group significantly increased the number of mitochondria compared to the shNC+CLP group (cells/HP: 11.250±2.063 vs. 10.375±1.375, P < 0.05). The expression of mtDNA in shNC+CLP group was markedly reduced compared with shNC+Sham group (copies: 0.842±0.035 vs. 1.002±0.064, P < 0.05). Although no difference was detected in the mtDNA expression between shD3+CLP group and shNC+CLP group, but significant increase was found when compared with the shD3+Sham group (copies: 0.758±0.035 vs. 0.474±0.050, P < 0.05). In the shD3+CLP group, PGC1α expression was significantly improved at both transcriptional and protein levels relative to the shNC+CLP group [PGC1α mRNA (2-ΔΔCt): 1.49±0.13 vs. 0.68±0.06, PGC1α/β-Tubulin: 0.76±0.02 vs. 0.62±0.04, both P < 0.05]. (2) In vitro experiments: post-24-hour LPS treatment of C2C12 cells, the cellular localization of PGC1α became diffuse; interference with Dio3 expression promoted PGC1α translocation to the perinuclear region and nucleus. Moreover, the acetylated PGC1α level in the shD3+LPS group was significantly lower than that in the shNC+LPS group (acetylated PGC1α/β-Tubulin: 0.59±0.01 vs. 1.24±0.01, P < 0.05), while the expression of the deacetylating agent SIRT1 was substantially elevated following Dio3 inhibition (SIRT1/β-Tubulin: 1.04±0.04 vs. 0.58±0.03, P < 0.05). When SIRT1 activity was inhibited by using EX527, PGC1α protein expression was notably decreased compared to the shD3+LPS group (PGC1α/β-Tubulin: 0.92±0.03 vs. 1.58±0.03, P < 0.05).
CONCLUSIONS: Inhibition of Dio3 in skeletal muscle reduced the acetylation of PGC1α through activating SIRT1, facilitating nuclear translocation of PGC1α, thereby offering protection against sepsis-induced skeletal muscle mitochondrial damage.
参考来源
- Wang G, Duan J, Cao K, et al. [Inhibition of type 3 deiodinase expression can improve mitochondrial function in skeletal muscle of sepsis by up-regulating peroxisome proliferator-activated receptor-γ coactivator-1α]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2024. PMID: 39238408. doi:10.3760/cma.j.cn121430-20231121-01003
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。